Phase 2RecruitingPriority 3 · Moderate priorityNCT06151106
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Plain-language summary
This Phase 2 trial is evaluating Chidamide combined with Duvillisib as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Chidamide combined with Duvillisib (DRUG): Specified dose on specified days
- Drugs / treatments
- Chidamide combined with Duvillisib
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details